Journal
ACS CHEMICAL NEUROSCIENCE
Volume 3, Issue 3, Pages 149-150Publisher
AMER CHEMICAL SOC
DOI: 10.1021/cn3000179
Keywords
Alzheimer's disease; amyloid hypothesis; gamma-secretase inhibitors; GSI
Ask authors/readers for more resources
BMS-708163 is a novel, sulfonamide containing gamma-secretase inhibitor from Bristol-Myers Squibb Co. currently in Phase II clinical trials for the treatment of Alzheimer's disease (AD).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available